KOM70144, PLpro inhibitor.

KOM70144, also known as PLpro inhibitor, is a potent inhibitor of papain-like protease (PLpro) with an IC50 of 2.6 µM. PLpro inhibitor inhibits SARS-CoV-2 PLpro with an IC50 of 5.0 µM and an EC50 of 21.0 µM. KOM70144 has CAS#1093070-14-4, no formal name For the convenience of scientific communication, we named it as KOM70144 (combined from Inchi key plus CAS#) according to Hodoodo Chemical Nomenclature.KOM70144 was first reported by Kiira Ratia et al, Proc Natl Acad Sci U S A. 2008;105(42):16119-16124. (compound 6)

Product information

CAS Number: 1093070-14-4

Molecular Weight: 346.42

Formula: C22H22N2O2

Synonym:

KOM70144

KOM-70144

KOM 70144

PLpro inhibitor

Chemical Name: (R)-5-acetamido-2-methyl-N-(1-(naphthalen-1-yl)ethyl)benzamide

Smiles: CC(=O)NC1=CC(C(=O)N[C@H](C)C2=CC=CC3=CC=CC=C32)=C(C)C=C1

InChiKey: KGPYBLOBHQLIET-OAHLLOKOSA-N

InChi: InChI=1S/C22H22N2O2/c1-14-11-12-18(24-16(3)25)13-21(14)22(26)23-15(2)19-10-6-8-17-7-4-5-9-20(17)19/h4-13,15H,1-3H3,(H,23,26)(H,24,25)/t15-/m1/s1

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: Soluble in DMSO

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

PLpro inhibitor is a potent inhibitor against the papain-like protease (PLpro) from the coronavirus that causes severe acute respiratory syndrome (SARS-CoV). PLpro inhibitor was found to have IC50 value of 2.6 μM. PLpro inhibitor display significant antiviral activity with EC50 values of 13.1 μM, without toxicity up to the highest concentration tested. Notably, the increasing antiviral potency correlates with the in vitro inhibition of PLpro, suggesting that the compounds work directly on the enzyme in cells.

References:

1. Characterization and Noncovalent Inhibition of the Deubiquitinase and deISGylase Activity of SARS-​CoV-​2 Papain-​Like Protease Quick View Other Sources. By Freitas, Brendan T.; Durie, Ian A.; Murray, Jackelyn; Longo, Jaron E.; Miller, Holden C.; Crich, David; Hogan, Robert Jeff; Tripp, Ralph A.; Pegan, Scott D. From ACS Infectious Diseases (2020), Ahead of Print. |
2. Compositions and methods for identification, assessment, prevention, and treatment of AML using USP10 biomarkers and modulators. By Buhrlage, Sara; Weisberg, Ellen. From PCT Int. Appl. (2018), WO 2018057618 A1.
3. Compounds and methods for treating respiratory diseases. Ghosh, Arun K.; Takayama, Jun; Mesecar, Andrew David; Johnson, Michael E.; Ratia, Kiira M.; Chaudhuri, Rima; Mulhearn, Debbie C. From U.S. Pat. Appl. Publ. (2011), US 20110269834 A1.
4. Compounds and methods for treating respiratory diseases . By Ghosh, Arun K.; Takayama, Jun. From PCT Int. Appl. (2010), WO 2010022355 A1 20100225.
5. Ratia K, Pegan S, Takayama J, et al. A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication. Proc Natl Acad Sci U S A. 2008;105(42):16119-16124.

Products are for research use only. Not for human use.